Effect of montelukast in treatment of gastroenteritis

Evaluation efficacy of montelukast in children gastroenteritis

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180624040213N3

Enrollment

Registered

2022-02-01

Start date

2021-12-11

Completion date

Unknown

Last updated

2022-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diarrhea.

Interventions

Intervention 1: Control group: All patients in the control group receive standard gastroenteritis treatment. Routine treatment of gastroenteritis includes serum therapy and zinc sulfate syrup). Receiv

Eligibility

Sex/Gender

All

Age

2 Years to 12 Years

Inclusion criteria

Inclusion criteria: 1. All patients with gastroenteritis, at any age 2 to 12 years and of both sexes, boys and girls are included in the study. 2. Patients with incurable disease or dangerous disease other than gastroenteritis. 3. Satisfaction of patients or their trustees (informed consent will be obtained from patients or patient trustees to participate in the study.)

Exclusion criteria

Exclusion criteria: Patients who develop a disease other than gastroenteritis during the study or find drug allergies Refrain from collaborating with the research team during the study or refrain from taking medication and clinical examinations according to the study method.

Design outcomes

Primary

Measure	Time frame
Measurement of serum interleukin level 13. Timepoint: Measurement of serum interleukin level 13 at the beginning of the study and 14 days after consumption of Montelukast. Method of measurement: Analysis of covariance (ANCOVA) will be used to evaluate the effect of montelukast on IL13 (before and after treatment) in both groups.	—

Secondary

Measure	Time frame
Frequency of diarrhea and abdominal pain in the study of the effectiveness of Montelukast in the treatment of pediatric gastroenteritis. Timepoint: Evaluation of abdominal pain and frequency of diarrhea and measurement of serum level of interleukin 13 at the beginning of the study and 14 days after taking Montelukast. Method of measurement: How to measure the frequency of diarrhea excretion according to Bristol criteria, Evaluation of abdominal pain based on criteria Visual Analogue.	—

Measure

Time frame

Frequency of diarrhea and abdominal pain in the study of the effectiveness of Montelukast in the treatment of pediatric gastroenteritis. Timepoint: Evaluation of abdominal pain and frequency of diarrhea and measurement of serum level of interleukin 13 at the beginning of the study and 14 days after taking Montelukast. Method of measurement: How to measure the frequency of diarrhea excretion according to Bristol criteria, Evaluation of abdominal pain based on criteria Visual Analogue.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHossein Najafzadehvarzi

Babol University of Medical Sciences

najafzadehvarzi@gmail.com+98 11 3247 6421

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026